CO2022014093A2 - Compuestos para su uso en afecciones inflamatorias - Google Patents
Compuestos para su uso en afecciones inflamatoriasInfo
- Publication number
- CO2022014093A2 CO2022014093A2 CONC2022/0014093A CO2022014093A CO2022014093A2 CO 2022014093 A2 CO2022014093 A2 CO 2022014093A2 CO 2022014093 A CO2022014093 A CO 2022014093A CO 2022014093 A2 CO2022014093 A2 CO 2022014093A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- inflammatory conditions
- inflammation
- relates
- toll
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382815 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| PCT/EP2021/055187 WO2021175857A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014093A2 true CO2022014093A2 (es) | 2022-11-18 |
Family
ID=74732953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014093A CO2022014093A2 (es) | 2020-03-02 | 2022-09-30 | Compuestos para su uso en afecciones inflamatorias |
| CONC2022/0014031A CO2022014031A2 (es) | 2020-03-02 | 2022-09-30 | Compuestos para su uso en infecciones víricas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014031A CO2022014031A2 (es) | 2020-03-02 | 2022-09-30 | Compuestos para su uso en infecciones víricas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20230159594A1 (https=) |
| EP (2) | EP4114433A2 (https=) |
| JP (2) | JP2023517536A (https=) |
| KR (2) | KR20220151643A (https=) |
| CN (2) | CN115461067A (https=) |
| AU (2) | AU2021232535A1 (https=) |
| BR (2) | BR112022016604A2 (https=) |
| CA (2) | CA3169540A1 (https=) |
| CL (2) | CL2022002396A1 (https=) |
| CO (2) | CO2022014093A2 (https=) |
| IL (2) | IL296069A (https=) |
| MX (2) | MX2022010926A (https=) |
| PE (2) | PE20230606A1 (https=) |
| PY (2) | PY2117301A (https=) |
| TW (2) | TWI908772B (https=) |
| UY (2) | UY39109A (https=) |
| WO (2) | WO2021175831A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230158102A1 (en) * | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in the treatment of coronavirus infection |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
| AU2021231521A1 (en) * | 2020-03-02 | 2022-10-06 | Pharma Mar, S.A. | PLD for use in combination in the treatment of coronavirus |
| WO2024165764A1 (en) * | 2023-02-10 | 2024-08-15 | Pharma Mar, S.A. | Plitidepsin for use in the treatment of non-integrated dna viral infections |
| CN117285611B (zh) * | 2023-11-24 | 2024-02-09 | 中国海洋大学 | 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| WO1999052515A2 (de) * | 1998-04-14 | 1999-10-21 | Hassan Jomaa | Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen |
| CA2405779A1 (en) | 2000-04-07 | 2001-10-18 | The Trustees Of The University Of Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| DK1347743T3 (da) * | 2000-12-07 | 2006-07-03 | Univ Utrecht Holding Bv | Præparat til behandling af inflammatoriske lidelser |
| EP1596823A2 (en) * | 2003-02-21 | 2005-11-23 | Sun Pharmaceuticals Industries Ltd. | A stable ophthalmic composition |
| JP2006523214A (ja) | 2003-03-21 | 2006-10-12 | ジユーリー，マデレーン・エム | タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法 |
| WO2007101235A2 (en) * | 2006-02-28 | 2007-09-07 | Pharma Mar, S.A. | Improved antitumoral treatments |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| BR112012014624A8 (pt) * | 2009-12-15 | 2017-12-26 | Novartis Ag | suspensão homogênea de compostos de imunopotenciação e usos dos destes |
| US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
| GB201316524D0 (en) * | 2013-09-17 | 2013-10-30 | Medical Res Council | Biomarkers |
| JP2017526728A (ja) * | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| US11771739B2 (en) * | 2017-06-16 | 2023-10-03 | Vanderbilt University | Methods and compositions for treating microbial inflammation |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
-
2021
- 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
- 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
- 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en not_active Ceased
- 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
- 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
- 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
- 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en not_active Ceased
- 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
- 2021-03-02 IL IL296069A patent/IL296069A/en unknown
- 2021-03-02 PY PY202102117301A patent/PY2117301A/es unknown
- 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko active Pending
- 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
- 2021-03-02 PY PY202102117308A patent/PY2117308A/es unknown
- 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
- 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
- 2021-03-02 TW TW110107293A patent/TWI908772B/zh active
- 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko active Pending
- 2021-03-02 US US17/908,533 patent/US20230159594A1/en active Pending
- 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
- 2021-03-02 UY UY0001039109A patent/UY39109A/es unknown
- 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
- 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
- 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
- 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
- 2021-03-02 IL IL296068A patent/IL296068A/en unknown
- 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
- 2021-03-02 UY UY0001039110A patent/UY39110A/es unknown
- 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
- 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
- 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
-
2022
- 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
- 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
- 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
- 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014093A2 (es) | Compuestos para su uso en afecciones inflamatorias | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| AR119389A1 (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
| HN2008001464A (es) | Formulaciones para administrcion parenteral de compuestos y sus usos | |
| GT201300128A (es) | Variantes de fc silenciosas de los anticuerpos anti-cd40 | |
| DOP2013000036A (es) | Derivados de ciclobutano como inhibidores de jak | |
| MX2011007647A (es) | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CR20180029A (es) | Inhibidores peotídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
| PA8805801A1 (es) | Agonistas novedosos de los receptores de glucorticoides | |
| CL2020003447A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
| NI201900075A (es) | Compuesto moduladores del receptor de hidrocarburos de arilo (ahr) | |
| CR20190392A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| MX2018005589A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| UY32675A (es) | Nuevos agonistas del receptor de glucocorticoides | |
| CR20150496A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| CL2020002177A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas | |
| MX2019000428A (es) | Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori. | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| CO6620038A2 (es) | Compuestos de adenosina y su uso | |
| MX365438B (es) | Compuestos de tipo 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores mglur2. | |
| ECSP088176A (es) | Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6 | |
| CL2022002589A1 (es) | Tratamiento de trastornos respiratorios | |
| SV2011003784A (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida |